Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
NCT03137537 · Dana-Farber Cancer Institute · PHASE2 · terminated · last registry update 2022-02-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding terminated” | – | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCN4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-26Phase 3 first posted: The Young Investigator Group of Cardiovascular Research, Ivabradine 7.5Mg Tab + DOBUTamine Injectable Solution (NCT05594342)
- 2022-10-14Phase 3 first posted: Instituto Nacional de Cardiologia Ignacio Chavez, Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID + Empagliflozin 10 MG OD (NCT05580510)
- 2022-03-24Phase 3 first posted: Universitätsklinikum Hamburg-Eppendorf, a drug against HCN4 (NCT05293080)
- 2022-03-15Phase 3 first posted: Jagiellonian University, Ivabradine + Placebo (NCT05279651)
- 2021-06-29Results posted on the registry: University of California, San Diego, Ivabradine + Placebo (NCT03182725)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision